Meropenem （ IV 120min）
Phase 3Small molecule
Qilu Pharmaceutical Co., Ltd.Meropenem （ IV 120min） is one of 9 small molecule programs targeting Enterobacteriaceae Infections. It is currently in Phase 3.
1
Indications
4
Total Trials
3
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Enterobacteriaceae Infections
#DrugCompanyPhaseTrials
1Maxipime
PfizerApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Merrem
BB. Braun Medical Inc.
Approved
Primaxin
PfizerPhase 3
Coly-Mycin M
PParkedale
Phase 3
Best Available Therapy
NovartisPhase 3
Ceftazidime-Avibactam
PfizerPhase 3
Meropenem （ IV 120min）
Qilu Pharmaceutical Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy and Safety2 trials
Enterobacteriaceae Infections1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Meropenem （ IV 120min）. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details